Epilepsy and paroxysmal conditions

Advanced search


Full Text:


Data on carbamazepine prolonged dosage forms use for treatment of epilepsy are presented in current review. Expediency of carbamazepine prolonged forms use in patients with different epilepsy forms and types of seizures is demonstrated. Besides its efficacy for stopping epileptic seizures prolonged dosage form of carbamazepine has stable plasma concentration, that is associated with better tolerability profile.

About the Authors

G. N. Avakyan
Chair of Neurology and Neurosurgery, GBOU VPO Russian National Investigational Medical University named after N.I. Pirogov, Ministry of Health and Social Development of the Russian Federation (Moscow)
Russian Federation

S. G. Burd
Chair of Neurology and Neurosurgery, GBOU VPO Russian National Investigational Medical University named after N.I. Pirogov, Ministry of Health and Social Development of the Russian Federation (Moscow)
Russian Federation


1. Громов С.А., Хоршев С.К., Михайлов В.А.Оптимизация терапии эпилепсии финлепсином. Журнал неврологии и психиатрии. 2000; 9: 32-35.

2. Вейн А.М., Воробьева О.В. Оптимизация тактики терапии симптоматических парциальных эпилепсий с использованием ретардной формы карбамазепина. В кн.: EPI’2000 II Восточно-европейская конференция “Эпилепсия и клиническая нейрофизиология”. Крым, Гурзуф. 2000; с. 193-194.

3. Aldenkamp A.P., Alpherts W.C., Moerland M.C., Ottevanger N., Van Parys J.A. Epilepsia. 1987 Sep-Oct; 28 (5): 507-14. Controlled release carbamazepine: cognitive side effects in patients with epilepsy.

4. Bareggi S.R., Tata M.R., Guizzaro A., Pirola R., Parisi A., Monza C.G. Int Clin Psychopharmacol. 1994 Spring; 9(1): 9-16. Daily fluctuation of plasma levels with conventional and controlledrelease carbamazepine: correlation with adverse effects.

5. Bertilsson L., Tomson T. Clin Pharmacokinet. 1986 May-Jun; 11(3): 177-98. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11-epoxide. An update.

6. Brodie M.J. Lancet. 1990 Aug 11; 336 (8711) :350-4. Established anticonvulsants and treatment of refractory epilepsy.

7. Canger R., Altamura A.C., Belvedere O., Monaco F., Monza G.C., Muscas G.C., Mutani R., Panetta B., Pisani F., Zaccara G. Acta Neurol Scand. 1990 Jul; 82 (1): 9-13. Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study.

8. Cramer J.A., Mattson R.H., Prevey M.C., Scheyer R.D., Ovellette V.L. How often is medication taken as prescribed? A novel assessment technique. J. Am. Med. Ass., 1989; 261: 3273-3277.

9. De Deyn P.P., Mol L., de RidderVanderdeelen P., Eerdekens M. Seizure. 1994 Sep; 3 (3): 235-8. An open multicentre prospective study of the effects of monotherapy with controlled-release carbamazepine on newly diagnosed generalized tonic-clonic seizures.

10. Elphick M. (1989) Psychol Med. 1989 Aug;19(3):591-604. Clinical issues in the use of carbamazepine in psychiatry: a review.

11. Gigli G.L., Placidi F., Diomedi M., Maschio M., Silvestri G., Scalise A., Marciani M.G. Epilepsia. 1997 Jun; 38 (6): 696-701. Nocturnal sleep and daytime somnolence in untreated patients with temporal lobe epilepsy: changes after treatment with controlled-release carbamazepine.

12. Gillham R.A., Williams N., Wiedmann K., Butler E., Larkin J.G., Brodie M.J. J Neurol Neurosurg Psychiatry. 1988 Jul; 51 (7): 929-33. Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients.

13. Giustizieri M., Armogida M., Berretta N., Federici M., Piccirilli S., Mercuri N.B., Nistico R. Synapse. 2008 Oct; 62 (10): 783- 9. Differential effect of carbamazepine and oxcarbazepine on excitatory synaptic transmission in rat hippocampus.

14. Höppener R.J., Kuyer A., Meijer J.W., Hulsman J. Epilepsia. 1980 Aug; 21 (4): 341- 50. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects.

15. Kammerer M., Rassner M.P., Freiman T.M., Feuerstein T.J. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jul; 384 (1): 47-57. doi: 10.1007/s00210-011-0636-8. Effects of antiepileptic drugs on GABA release from rat and human neocortical synaptosomes.

16. Macphee G.J., Butler E., Brodie M.J. Epilepsia. 1987 May-Jun; 28 (3): 286-94. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism.

17. Mirza W.U., Rak I.W., Thadani V.M., Cereghino J.J., Garnett W.R., Brown L.M., Zhang Y., Belendiuk G.W. Neurology. 1998 Dec; 51 (6): 1727-9. Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures.

18. Pieters M.S., Jennekens-Schinkel A., Stijnen T., Edelbroek P.M., Brouwer O.F., Liauw L., Heyer A., Lanser J.B., Peters A.C. Epilepsia. 1992 Nov-Dec; 33 (6): 1137-44. Carbamazepine (CBZ) controlled release compared with conventional CBZ: a controlled study of attention and vigilance in children with epilepsy.

19. Powell G., Saunders M., Marson A.G. Cochrane Database Syst Rev. 2010 Jan 20; (1): CD007124. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.

20. Riva R., Albani F., Ambrosetto G., Contin M., Cortelli P., Perucca E., Baruzzi A. Epilepsia. 1984 Aug; 25 (4): 476-81. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects.

21. Sitges M., Guarneros A., Nekrassov V. Neuropharmacology. 2007 Dec; 53(7): 854-62. Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release.

22. Tomson T. Arch Neurol. 1984 Aug; 41(8): 830-4. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects.

23. Vojvodić N.M., Sokić D.V., Janković S.M., Lević Z., Srp Arh Celok Lek. 2002 Jan-Feb; 130(1- 2): 19-26. A practical study of the efficacy of a delayed-action preparation of carbamazepine Tegretol CR 400) in the treatment of patients with partial epilepsy.

24. Vorob’eva O.V. Optimizing the therapy of symptomatic partial epilepsy with sustained release carbamazepine Zh Nevrol Psikhiatr Im S S Korsakova 2001; 101(3): 24-8.

25. Отчет о сравнительном исследовании биоэквивалентности карбамазепина (таблеток по 200 мг и по 400 мг) «Карбамазепин-АКРИ ретард» (test) производства ОАО «АКРИХИН», Россия и «Тегретол ЦР» (standard) производства фирмы «Новартис Фарма», Швейцария/ РГМУ, 2003. 67 с.


For citations:


Views: 534

ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)